EFFECT OF ELUXADOLINE ON ABDOMINAL AND BOWEL SYMPTOMS OVER TIME IN PHASE 3 CLINICAL TRIALS IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH DIARRHOEA (IBS-D)

被引：0
|
作者：
Harris, L. A. [1 ]
Lucak, S. [2 ]
Chang, L. [3 ]
Dove, L. S. [4 ]
Covington, P. S. [4 ]
机构：
[1] Mayo Clin, Scottsdale, AZ USA
[2] Weill Cornell Med, New York, NY USA
[3] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[4] Furiex Pharmaceut Inc, Parsippany, NJ USA
来源：
GUT | 2016年 / 65卷
关键词：
D O I：
10.1136/gutjnl-2016-312388.219
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
PTU-133
引用
收藏
页码：A122 / A123
页数：2
相关论文
共 50 条
  • [1] Effect of Eluxadoline on Abdominal and Bowel Symptoms Over Time in Phase 3 Clinical Trials in Patients With Irritable Bowel Syndrome With Diarrhea
    Harris, Lucinda
    Lucak, Susan
    Chang, Lin
    Dove, Leonard S.
    Covington, Paul S.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 : S748 - S748
  • [2] ELUXADOLINE DEMONSTRATES EFFICACY FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME (IBS) WITH DIARRHOEA (IBS-D) AMONG MULTIPLE CLINICALLY RELEVANT PATIENT SUBGROUPS
    Lacy, B.
    Chey, W.
    Lembo, A.
    Dove, L. S.
    Covington, P. S.
    [J]. GUT, 2016, 65 : A42 - A43
  • [3] MAPPING THE IRRITABLE BOWEL SYNDROME QUALITY OF LIFE MEASURE (IBS-QOL) TO EQ-5D IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH DIARRHOEA (IBS-D)
    Bjorner, J. B.
    Rendas-Baum, R.
    Carson, R. T.
    Boer, R.
    Tucker, C.
    Andrae, D. A.
    Brazier, J. E.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A379 - A379
  • [4] ORIGIN OF INCREASED FECAL SERINE PROTEASE IN PATIENTS WITH IRRITABLE BOWEL SYNDROME AND DIARRHOEA (IBS-D)
    Garsed, K.
    Singh, G.
    Tooth, D.
    Lam, C.
    Banwait, R.
    Lingaya, M.
    Spiller, R.
    [J]. GUT, 2011, 60 : A25 - A25
  • [5] Effects of Eluxadoline on Abdominal Pain in Patients With Irritable Bowel Syndrome With Diarrhea: Results of 2 Phase 3 Clinical Trials
    Lembo, Anthony
    Dove, Scott
    Andrae, David
    Turner, Lisa
    Davenport, J. Michael
    Covington, Paul S.
    [J]. GASTROENTEROLOGY, 2015, 148 (04) : S493 - S493
  • [6] A PHASE II STUDY OF LIVE BIOTHERAPEUTIC BLAUTIX IN IRRITABLE BOWEL SYNDROME (IBS) PATIENTS WITH SUBTYPES IBS-D AND IBS-D
    Stevenson, Alex
    Glasmacher, Axel
    Markinson, Louise
    Badham, Charlie
    Quigley, Eamonn M.
    [J]. GASTROENTEROLOGY, 2021, 160 (06) : S571 - S571
  • [7] Eluxadoline for the treatment of irritable bowel syndrome with diarrhea (IBS-D): results of two randomized, double-blind, placebo-controlled Phase 3 clinical trials
    Covington, Paul
    [J]. PHARMACOTHERAPY, 2015, 35 (11): : E189 - E189
  • [8] PHENOTYPING THE EARLY MORNING RUSH (EMR) IN PATIENTS WITH DIARRHOEA PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS-D)
    Garsed, K.
    Hastings, M.
    Lam, C.
    Whorwell, P.
    Spiller, R.
    [J]. GUT, 2012, 61 : A318 - A318
  • [9] Efficacy of Rifaximin on Bowel Movement Urgency in Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D): A Pooled Analysis of 3 Phase 3 Trials
    Pimentel, Mark
    Cash, Brooks D.
    Wolf, Ray
    Lembo, Anthony J.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S253 - S254
  • [10] The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D)
    Min, Yang Won
    Rhee, Poong-Lyul
    [J]. THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2015, 8 (03) : 136 - 142
12345